Strain of respiratory syncytial virus (RSV) for vaccine and therapeutic research and development.
- Higher early viral load.
- Induces greater necrotic airway damage and neurophil infiltration.
RSV is a highly contagious and ubiquitous virus that causes respiratory tract infections in individuals of all ages, particularly young children and the elderly. In the US, 75,000-125,000 RSV-related hospitalizations are reported annually among infants <1 year of age. Worldwide the virus is also responsible for 160,000 deaths per year. Currently, no effective vaccine against RSV exists and treatment is limited to a non-vaccine prophylactic medication and supportive care.
Researchers generated a recombinant F-chimeric RSV by replacing the F gene of A2 with the F gene of line 2-20, generating A2-2-20F. Infection of mice with this line resulted in a higher early viral load and higher levels of subsequent pulmonary mucin expression than infection with the A2 strain. A2-2-20F infection induced greater necrotic airway damage and neurophil infiltration than A2 infection. This leads to death in most mice infected. Combined these effects make this viral line a strong candidate for use during in vivo testing of vaccine or small molecules for RSV.
This strain has been developed and used for vaccine candidate screening in the lab.